Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study
| Autor: | Chiara Costanzi, Daniele Generali, Ilaria Zangrandi, Valeria De Giuli, Fabio Malberti, Maria Rosa Cappelletti, Giancarlo Bosio, Andrea Machiavelli, Marianna Sirico, Antonio Fioravanti, Guglielmo Giannotti, Angelo Pan, Sophie Testa, Ottavia Bernocchi, Fabiola Giudici, Alessia Giossi, Erika Maria Viola, Alfredo Molteni, Marina Foramitti, Alessandro Morandini, Antonio Cuzzoli, Matteo Giorgi-Pierfranceschi, Maurizio Scaltriti, Sergio Venturini, Giulia Chiodelli, Chiara Campana, Alessia Zoncada, Luca Pianta, Laura Romanini, Rosa Angela Tira |
|---|---|
| Přispěvatelé: | Generali, D., Bosio, G., Malberti, F., Cuzzoli, A., Testa, S., Romanini, L., Fioravanti, A., Morandini, A., Pianta, L., Giannotti, G., Viola, E. M., Giorgi-Pierfranceschi, M., Foramitti, M., Tira, R. A., Zangrandi, I., Chiodelli, G., Machiavelli, A., Cappelletti, M. R., Giossi, A., De Giuli, V., Costanzi, C., Campana, C., Bernocchi, O., Sirico, M., Zoncada, A., Molteni, A., Venturini, S., Giudici, F., Scaltriti, M., Pan, A. |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Male medicine.medical_treatment Cohort Studies 0302 clinical medicine Monoclonal 80 and over 030212 general & internal medicine Viral Prospective Studies Prospective cohort study Humanized Aged 80 and over General Medicine Middle Aged Hospitalization Infectious Diseases medicine.anatomical_structure Treatment Outcome Settore SECS-S/01 - STATISTICA Cohort Female Case-Control Studie medicine.drug Cohort study Human Microbiology (medical) Adult medicine.medical_specialty Canakinumab 030106 microbiology Pneumonia Viral Antibodies Monoclonal Humanized Article Antibodies lcsh:Infectious and parasitic diseases 03 medical and health sciences Internal medicine medicine Humans lcsh:RC109-216 Aged Mechanical ventilation Lung business.industry SARS-CoV-2 Case-control study COVID-19 Pneumonia medicine.disease Prospective Studie Case-Control Studies Cohort Studie business |
| Zdroj: | International Journal of Infectious Diseases, Vol 104, Iss, Pp 433-440 (2021) International Journal of Infectious Diseases |
| Popis: | Highlights • Canakinumab is an IL-1β antibody that neutralizes the activity of IL-1β. • The effects of canakinumab in patients with COVID-19-related pneumonia were studied. • 33 patients received canakinumab and 15 received institutional standard of care. • Treatment with canakinumab rapidly restored normal oxygen status. • Canakinumab was also associated with favorable prognosis versus SoC. Objectives Canakinumab is an IL-1β antibody that neutralizes the activity of IL-1β. We studied the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia. Design The aim of our study was to evaluate the reduction in duration of hospitalization with adequate oxygen status. Forty-eight patients with moderate COVID-19-related pneumonia were asked to participate in the prospective case-control study; 33 patients (Cases) signed informed consent and received canakinumab (Cohort 1); 15 patients (Controls) refused to receive the experimental drug and received institutional standard of care (SoC), (Cohort 2). Results Hospital discharge within 21 days was seen in 63% of patients in Cohort 1 vs. 0% in Cohort 2 (median 14 vs 26 days, respectively; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|